<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="197">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01638949</url>
  </required_header>
  <id_info>
    <org_study_id>2011-A01493-38</org_study_id>
    <nct_id>NCT01638949</nct_id>
  </id_info>
  <brief_title>Multi-modal Neuroimaging in Alzheimer's Disease</brief_title>
  <acronym>IMAP+</acronym>
  <official_title>Study of the Predictive Markers and the Pathophysiological Mechanisms of Alzheimer's Disease: Transverse and Longitudinal Approach in Anatomical and Functional Multimodal Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alzheimer's disease (AD) is a major public health problem due to its socio-economic weight.&#xD;
      An early diagnosis of AD is urgently needed as it would constitute a determinant breakthrough&#xD;
      from a social, financial and research standpoints. Therefore, the investigators need&#xD;
      predictive markers of AD, and neuroimaging is a particularly promising tool, especially when&#xD;
      using complementary neuroimaging techniques and a longitudinal design, allowing to assess the&#xD;
      relationships between the different biomarkers of the disease, their dynamic and their&#xD;
      chronology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The three main objectives of this project are:&#xD;
&#xD;
        -  To Identify, compare and combine the predictive markers of AD,&#xD;
&#xD;
        -  To better understand the pathophysiologic mechanisms of AD,&#xD;
&#xD;
        -  To study the ability of different neuroimaging techniques to monitor AD's evolution.&#xD;
&#xD;
      For these purposes, detailed neuropsychological evaluations, biological measures and brain&#xD;
      structural &amp; functional imaging measures are associated for a fully-comprehensive description&#xD;
      of the different manifestations of AD through disease progression and toward identifying&#xD;
      early markers.&#xD;
&#xD;
      Subjects are evaluated using neuropsychological tests of episodic memory (encoding vs.&#xD;
      retrieval), executive functions (inhibition, flexibility, and updating processes),&#xD;
      self-judgment, theory of mind, mental imagery and verbal fluency. A FDG-PET measure of&#xD;
      resting state glucose consumption, an AV45-PET measure of amyloid deposition as well as&#xD;
      anatomical, resting-state and activation fMRI scans are performed for each volonteer. In&#xD;
      addition, blood and cerebro-spinal fluid samples will be performed to determine different&#xD;
      biomarkers (Aβ1-40, Aβ1-42 and tPA as circulating blood proteins and Aβ40, Aβ42, tau and its&#xD;
      phosphorylated form in CSF). The investigators also study the polymorphism of Apolipoprotein&#xD;
      E as a genetic risk factor of AD.&#xD;
&#xD;
      One hundred and twenty healthy controls (40 young, 40 middle age and 40 elderly), 40 Mild&#xD;
      Cognitive Impairment patients (MCI; i.e. isolated memory impairment and increased risk of&#xD;
      developing AD) and 30 AD patients will be selected. Participants with increased risk of&#xD;
      developing AD and without objective evidence will be also studied: 50 asymptomatic subjects&#xD;
      from families carrying a genetic mutation with an autosomal dominant transmission (NORMA) and&#xD;
      40 Subjective Cognitive Impairment patients (SCI).&#xD;
&#xD;
      Clinical follow-up of patients will be completed during 36 months (18 months for AD&#xD;
      patients), as a neuropsychological evaluation every 6 months. Comparable neuropsychological&#xD;
      and imaging exams will be proposed once again after 18 months for all participants as well as&#xD;
      after 36 months for elderly controls, NORMA and SCI &amp; MCI patients.&#xD;
&#xD;
      To study and compare the effectiveness of different in vivo markers (to predict cognitive&#xD;
      decline in populations at risk of developing AD), each data set (i.e. modality) will be first&#xD;
      analyzed independently from one another (intra-modality analyses), including inter-group&#xD;
      comparisons, correlations and connectivity analyses, as well as longitudinal assessment of&#xD;
      cognitive, biological and brain changes. Baseline data will also be analyzed in function of&#xD;
      patient's clinical evolution to assess their predictive value. Comparisons and correlations&#xD;
      between the different patterns of alterations will then be performed through inter-modality&#xD;
      analyses. More specifically, the investigators will address the questions of the&#xD;
      relationships between cognitive and cerebral alterations and structural / functional brain&#xD;
      changes over our different patient samples, neuroimaging data sets, and through disease&#xD;
      evolution.&#xD;
&#xD;
      This project is expected to identify specific and early markers of the MA and also to compare&#xD;
      the diagnostic efficiency of different measures. It should contribute to better understand&#xD;
      brain and cognitive alterations in AD. Finally, the investigators will be able to appreciate&#xD;
      the dynamic properties of these alterations in the evolution of the disease through the&#xD;
      longitudinal study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of volume change of whole brain, hippocampus and other structural MRI measures</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Decline as measured by: Cognitive Tests, Activities of Daily Living, and CDR Sum of Boxes</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of change on each specified biochemical biomarker</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of change of glucose metabolism (FDG-PET)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Extent of amyloid deposition as measured by 18F-AV45</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Group differences for each imaging and biomarker measurement</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>APOE genotype</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">295</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Young controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle age controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asymptomatic subjects from families carrying a genetic mutation with an autosomal dominant transmission</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjectif Cognitive Impariment patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Cognitive Impairment patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alzheimer Disease patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non degenerative amnsesic syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Memory assessment</intervention_name>
    <description>Neuropsycological tests including clinical and original tests to compare differences between each populations.</description>
    <arm_group_label>Alzheimer Disease patients</arm_group_label>
    <arm_group_label>Asymptomatic subjects</arm_group_label>
    <arm_group_label>Elderly controls</arm_group_label>
    <arm_group_label>Middle age controls</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment patients</arm_group_label>
    <arm_group_label>Non degenerative amnsesic syndrome</arm_group_label>
    <arm_group_label>Subjectif Cognitive Impariment patients</arm_group_label>
    <arm_group_label>Young controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Circulating biomarkers measure</intervention_name>
    <description>ELISA tests from blood samples to compare differences between each populations.</description>
    <arm_group_label>Alzheimer Disease patients</arm_group_label>
    <arm_group_label>Asymptomatic subjects</arm_group_label>
    <arm_group_label>Elderly controls</arm_group_label>
    <arm_group_label>Middle age controls</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment patients</arm_group_label>
    <arm_group_label>Non degenerative amnsesic syndrome</arm_group_label>
    <arm_group_label>Subjectif Cognitive Impariment patients</arm_group_label>
    <arm_group_label>Young controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ApoE4</intervention_name>
    <description>Evaluation of apolipoprotein E polymorphism as a risk factor.</description>
    <arm_group_label>Alzheimer Disease patients</arm_group_label>
    <arm_group_label>Asymptomatic subjects</arm_group_label>
    <arm_group_label>Elderly controls</arm_group_label>
    <arm_group_label>Middle age controls</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment patients</arm_group_label>
    <arm_group_label>Non degenerative amnsesic syndrome</arm_group_label>
    <arm_group_label>Subjectif Cognitive Impariment patients</arm_group_label>
    <arm_group_label>Young controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brain imaging examination MRI and PET examinations</intervention_name>
    <description>Structural and functional MRI FDG-PET to compare differences between each populations.</description>
    <arm_group_label>Alzheimer Disease patients</arm_group_label>
    <arm_group_label>Asymptomatic subjects</arm_group_label>
    <arm_group_label>Elderly controls</arm_group_label>
    <arm_group_label>Middle age controls</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment patients</arm_group_label>
    <arm_group_label>Non degenerative amnsesic syndrome</arm_group_label>
    <arm_group_label>Subjectif Cognitive Impariment patients</arm_group_label>
    <arm_group_label>Young controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          -  Education level &gt; 7 years&#xD;
&#xD;
          -  Native language: French&#xD;
&#xD;
          -  Medical, neurological, neuropsychological and neuroradiological depth in accordance&#xD;
             with the criteria for inclusion and exclusion-specific population, that is to say:&#xD;
&#xD;
               -  Healthy young volunteers: between 18 and 40 years old; normal performances&#xD;
                  compared to the age and the educational level for all tests of the diagnostic&#xD;
                  battery (± 1.65 SD).&#xD;
&#xD;
               -  Healthy Middle-aged volunteers: between 40 and 60 years old; without memory&#xD;
                  complaints, normal performances compared to the age and the educational level for&#xD;
                  all tests of the diagnostic battery (± 1.65 SD).&#xD;
&#xD;
               -  Healthy Elderly volunteers: over 60 years old, living at home, without memory&#xD;
                  complaints, normal performances compared to the age and the educational level for&#xD;
                  all tests of the diagnostic battery (± 1.65 SD).&#xD;
&#xD;
               -  SCI patients: over 60 years old ; memory complaints; memory complaint ; normal&#xD;
                  performances compared to the age and the educational level for all tests of the&#xD;
                  diagnostic battery (± 1.65 SD).&#xD;
&#xD;
               -  MCI patients: presenting the current criteria for amnestic MCI including: i)&#xD;
                  memory complaint, ii) deficits of the episodic memory (lower performance of at&#xD;
                  least 1.65 SD from the norm for age and cultural level for one or more scores of&#xD;
                  episodic memory and iii) normal performances compared to the age and the&#xD;
                  educational level of all other cognitive functions as memory, including tests to&#xD;
                  assess cognitive abilities.&#xD;
&#xD;
               -  Alzheimer's patients: presenting the standard criteria of NINCDS-ADRDA probable&#xD;
                  Alzheimer's disease, including abnormal global cognitive function and deficits in&#xD;
                  at least two cognitive domains identified by the diagnostic battery and a mild to&#xD;
                  moderate Alzheimer's disease (MMSE ≥ 15).&#xD;
&#xD;
        Exclusion Criteria :&#xD;
&#xD;
          -  The sudden onset of cognitive impairments (as opposed to their slow and gradual&#xD;
             installation in Alzheimer's disease)&#xD;
&#xD;
          -  A chronic neurological, psychiatric, endocrine, hepatic or infectious complaint&#xD;
&#xD;
          -  A history of major disease (an uncontrolled diabetes, a lung, heart, metabolic,&#xD;
             hematologic, endocrine disease or a severe cancer)&#xD;
&#xD;
          -  A medication that may interfere with memory or metabolic measures&#xD;
&#xD;
          -  A alcohol or drugs abuse&#xD;
&#xD;
          -  The cons-indications to MRI (claustrophobia, metallic object in the body)&#xD;
&#xD;
          -  A predominantly left-hand (score below 50% in Edinburgh Inventory)&#xD;
&#xD;
          -  Protected adults, and persons not affiliated with a social security system will not&#xD;
             participate in this study&#xD;
&#xD;
          -  The inclusion of a participant in another biomedical research protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent de La Sayette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien Chavant</last_name>
    <phone>+33231065495</phone>
    <email>memoire-recherche.caen@inserm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>GIP Cyceron</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inserm - EPHE - University of Caen U1077</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>May 22, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2012</study_first_posted>
  <last_update_submitted>April 8, 2014</last_update_submitted>
  <last_update_submitted_qc>April 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>MCI</keyword>
  <keyword>genetic</keyword>
  <keyword>AV45-PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

